MINDPAX and EVERSANA announce US commercialization partnership to launch revolutionary digital therapeutic solution for bipolar disorders

CHICAGO, Oct. 12, 2021 /PRNewswire/ — The leadership team at MINDPAX Inc., the leading digital therapeutic company focused on bipolar disorders, today announces its partnership with EVERSANA™ to launch and commercialize its therapeutics in the United States. MINDPAX combines remote clinical assessment and targeted digital therapy to improve patients’ clinical conditions. The solution provides personalized therapeutic interventions to bipolar patients in times of need.

Read the source article at prnewswire.co.uk
2021-10-12 16:00:00